There was a lower incidence of grade 3 or 4 thrombocytopenia in patients receiving TPO-RAs (33.49%) compared to those receiving a placebo (48.78%) in both chemotherapy groups (RR = 0.69, 95% CI:0.52–0.91, P < 0.05). The gene discussed is TPO; the disease is Thrombocytopenia.